Jinling Huang

• Lead business development and expansion in Europe, focusing on fostering partnerships with biotech and pharmaceutical companies. • Expand market reach by promoting BioMed Linkage’s service portfolio in pharmacology, DMPK, toxicology, drug manufacturing, and regulatory support. Drive engagement with European clients to deliver end-to-end solutions, from early research to GMP-certified clinical trial production. • Manage high-value partnerships to enhance BioMed Linkage’s presence and reputation as a premier CRO and CDMO service provider. • Provide strategic insights on navigating NMPA interactions and regulatory submissions for seamless project execution.

• Facilitated connections between European biotech companies and BioMed Linkage's comprehensive CRO and CDMO services in China. • Promoted the company’s core offerings, including drug manufacturing, pharmacology, DMPK, toxicology, and regulatory support, to prospective clients. • Supported clients in identifying tailored solutions to streamline product development and regulatory activities. • Built foundational relationships with key stakeholders, laying the groundwork for the company’s European expansion.

• Spearheading the development and application of AI technologies in biologics design and development, streamlining drug discovery and decision-making processes. • Building an AI automation platform-biopharma.ai that monitors multiple biopharma tracks and updates the latest news, providing real-time insights for R&D, regulatory, and business leaders. • Designing specialized AI assistants for different roles in the biopharma industry, including Regulatory, CMC, Clinical, and Business Development. • Evaluating, screening, and managing CRO and CDMO partners to support global drug development initiatives. • Leading fundraising and partnership activities to drive innovation and scale AI-powered biologics programs.

• Computational Biologics Design: Conducted research on the de novo computational design of peptide binders, focusing on modulating TAR DNA-binding protein 43 aggregation in neurodegenerative diseases. • Advanced Techniques: Utilized tools such as AlphaFold2, RFdiffusion, ScanNet, HADDOCK, and Prodigy for protein structure prediction, molecular docking, and binding affinity evaluation. • Cyclic Peptide Design: Designed cyclic peptides targeting intracellular proteins, incorporating molecular dynamics (MD) simulations with GROMACS to assess membrane permeability and therapeutic viability. • In-Depth Biopharmaceutical Knowledge: Acquired extensive understanding of the design, production, and properties of biologics through advanced coursework and laboratory practice. • Publication and Collaboration: Contributed to a multi-omics study on NEC published in bioRxiv (2024), showcasing collaboration with international research teams.

• Secured licensing rights for the world’s largest rehabilitation service accreditation in China, driving market expansion. • Established partnerships with hospitals to launch rehabilitation training programs, enhancing service delivery. • Drafted and translated accreditation manuals, ensuring cultural relevance and accuracy. • Built relationships with key opinion leaders (KOLs) to boost visibility and influence in the healthcare sector. • Facilitated cross-border collaborations between Swedish and Chinese healthcare organizations.

• Conducted research on Alzheimer’s Disease (AD) using transgenic mouse models (TgAPParc mice) to study amyloid-beta (Aβ) deposition patterns and their relation to early-onset dementia. • Performed immunohistochemistry with specific antibodies (10D1 and 6E10) to investigate spatiotemporal progression and expression of amyloid plaques and human APP in brain regions. • Analyzed results to identify differences in Aβ distribution and hypothesized mechanisms of propagation in neurodegenerative diseases. • Supported the development of methodologies to understand the role of specific mutations (e.g., Arctic mutation E693G) in Aβ aggregation and its contribution to AD pathology.

• Contributed to the development and validation of lead compounds for neurodegenerative diseases, focusing on preclinical efficacy studies. • Literature Review and Innovation: Conducted comprehensive reviews of scientific literature to support assay development and integrated cutting-edge technologies into laboratory workflows. • Performed data analysis for validation studies, ensuring accurate interpretation of results to guide therapeutic development. • Supported the design and execution of in vitro and in vivo experiments, enhancing the understanding of lead compound mechanisms of action.